4-METHYL-1,2,3-THIADIAZOLE-5-CARBOXYLIC ACID


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SPWAXXURWTXASK-UHFFFAOYSA-N
Smiles	Cc1c(ccc2snnc12)C(=O)O
InChI	InChI=1S/C8H6N2O2S/c1-4-5(8(11)12)2-3-6-7(4)9-10-13-6/h2-3H,1H3,(H,11,12)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C8H6N2O2S
Molecular Weight	194.21
AlogP	2.12
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	91.32
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	13.0

Assay Description	Organism	Bioactivity
Fungicidal activity against Botryotinia fuckeliana assessed as growth inhibition at 50 ug/ml after 2 days	Botryotinia fuckeliana	96.4 %
Fungicidal activity against Fusarium graminearum assessed as growth inhibition at 50 ug/ml after 2 days	Fusarium graminearum	88.1 %
Fungicidal activity against Botryosphaeria berengeriana assessed as growth inhibition at 50 ug/ml after 2 days	Botryosphaeria berengeriana	84.89 %
Fungicidal activity against Mycosphaerella arachidis assessed as growth inhibition at 50 ug/ml after 2 days	Mycosphaerella arachidis	74.36 %
Fungicidal activity against Alternaria solani assessed as growth inhibition at 50 ug/ml after 2 days	Alternaria solani	77.44 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2228258
PubChem	18616050
SureChEMBL	SCHEMBL6986066

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).